1Lattice
Enabling Better Decisions

Lattice Technologies Private Limited
CIN: U74999DL2020PTC368952
PAN (Tax id): AAECL3217D, GSTIN: 07AAECL3217D1ZY

Date: July 24th 2026

To,

The Board of Directors
Molbio Diagnostics Limited
Plot No. L-46,
Phase II-D Verna Industrial Area, Verna,
Salcete, South Goa 403 722, Goa, India

Dear Sirs,

Proposed initial public offering of equity shares bearing face value of Rs. 1/- each (the "Equity Shares") of Molbio Diagnostics Limited (the "Company" and such offering as the "Offer")

We refer to your request dated July 24th 2026 regarding the content provided to you for your use of the following report prepared by Lattice Technologies Private Limited.

Molecular Diagnostics Industry Report – dated July 24th 2026 (the "**Report**")

As requested by you, we accord our no objection and give consent to you and your advisors on the Offer for including our name as "expert" in terms of the Companies Act, 2013, as amended, and reproducing a part or whole of the content (hereinafter referred to as "**Material**") made available to you as part of the above subscription of the Report, and the information contained in this letter and our engagement letter, in any document issued by the Company in connection with the Offer, including the updated draft red herring prospectus ("**UDRHP**") to be filed with the Securities and Exchange Board of India (the "**SEBI")** and BSE Limited and the National Stock Exchange of India Limited where the Equity Shares are proposed to be listed (the "**Stock Exchanges**"), the red herring prospectus ("**RHP**"**)** and the prospectus ("**Prospectus**") to be filed with the Registrar of Companies, Goa, Daman and Diu at Panaji ("**RoC**"), and thereafter with the SEBI and the Stock Exchanges or any other document to be issued, or filed in relation to the Offer, including in any presentation, publicity material, research reports, or other materials prepared, issued or filed by the Company or its advisors or their respective affiliates in relation to the Offer, collectively with the UDRHP, the RHP and the Prospectus, the "**Offer Documents**" and each individually an "**Offer Document**"**)** subject to the following:

- You are reproducing the Material on an "as is where is" basis, clearly mentioning the document source and the date of release.

In this regard, we undertake that no, inter alia, consent, approval, or permission will be required by the Company in the future in connection with using our name and/or contents of the Report, in full or in part. You agree and undertake (i) to comply with all applicable laws and regulations in relation to the Offer Materials and (ii) not to misrepresent, make any changes to, obliterate or tamper with the Report or present any part thereof out of context except in the case of the Material which has been approved by us. Further, you acknowledge and agree that Lattice Technologies Private Limited does not accept responsibility for the Offer Documents or any part thereof, except for the Report/Material.

Further, we accord our no objection and give our consent for the Report being made available on the website of the Company and to the inclusion of such weblink to the Report in the Offer Materials.

This letter does not impose any obligation on the Company or the Book Running Lead Managers to include in any Offer Documents, all or any part of the information with respect to which consent for disclosure is being granted pursuant to this letter.

We confirm that we are an independent firm with respect to the Company and the Book Running Lead Managers ("**BRLMs**").

We confirm that we are not, and have not in the past, been engaged or interested in the formation or promotion or management of the Company. We confirm that none of the Company, its promoters, directors, subsidiaries, group company or key managerial personnel or senior management personnel or selling shareholders or the BRLM(s) are our related parties as on the date of this letter, in accordance with the definition of 'related party' in Section 2(76) Companies Act, 2013 and the Securities and Exchange Board of India (Listing Obligations and Disclosure Obligations) Regulations, 2015, each as amended. Further, we confirm that we and our associates do not hold any Equity Shares of the Company

We further confirm that the procedures we have undertaken do not constitute an audit of the Company's historical financial statements, nor do they amount to an examination of prospective financial information., We do not express any opinion, warranty, representation, or other form of assurance on the historical or prospective financial statements included in or forming the basis of this report. Further, no financial, tax, environmental, accounting, or other due diligence has been carried out by us in respect of the Company.

We further confirm that we have, where required, obtained requisite consent that may be required from any governmental authority or other person in relation to any information used by us in our Report - *Molecular Diagnostics Industry Report* published on July 24^{th} 2026. We confirm that information contained in the Report has been obtained or derived from publicly available sources and interaction with industry participants, which we consider as true and reliable and after exercise of reasonable care and diligence by us.

We further confirm that there are no further consents, permission, approvals or intimation required for the quoting or sourcing of information and data or reproduction of content contained in the Material in any Offer Documents. We confirm that all information contained in the Material has been obtained by us from sources believed by us to be true and reliable and after exercise of due care and diligence by us.

We represent that our execution, delivery and performance of this consent have been duly authorised by all necessary actions (corporate or otherwise).

We undertake to inform the Company and BRLMs promptly, in writing of any changes to the above information until the date when the Equity Shares commence trading on the Stock Exchanges. In the absence of any such communication from us, the above-mentioned information should be considered as updated information until the Equity Shares commence trading on the Stock Exchanges, pursuant to the Offer.

This letter may be relied upon by the legal counsels, BRLMs and their affiliates appointed in relation to the Offer and to assist the BRLM(s) in conducting and documenting their investigation and due diligence in connection with the Offer.

We hereby consent for submission of this letter to the SEBI, Stock Exchanges, RoC, and any other legal, governmental or regulatory authority as may be required by law. We further consent to the aforementioned details being included for the records to be maintained by the BRLM(s) in connection with the Offer and in accordance with applicable laws.

We hereby consent to inclusion of the Report and this letter as part of the section titled "*Material Contracts and Documents for Inspection*" in the Offer Documents. Further, we consent to this letter and the Report being uploaded, as may be necessary, as part of the back-up documents to be retained in relation to the Offer on the online document repository platform established by each of the Stock Exchanges, in accordance with SEBI Circular No. SEBI/HO/CFD/CFD-TPD-1/P/CIR/2024/170 dated December 5, 2024, as amended

We hereby consent to this certificate being disclosed by the BRLMs, if required (i) by reason of any law, regulation, or order of a court or by any governmental or competent regulatory authority, or (ii) in seeking to establish a defense in connection with, or to avoid, any actual, potential or threatened legal, arbitral or regulatory proceeding or investigation.

We agree to keep strictly confidential, the non-public information, your request and this consent relating to the Offer until such time that: (A) such disclosure by us is approved by the Company in writing; or (B) such disclosure is required by law or regulation in which case we shall inform you about the same before the disclosure, where practical and legally permissible; or (C) such information is already in public domain or comes into public domain through no fault of ours.

For **Lattice Technologies Private Limited**

LATTICE TECHNOLOGIES PVT. LTD. DELHI

Sanya Agarwal
Group Head - Finance

Cc:

Kotak Mahindra Capital Company Limited 1st Floor, 27 BKC, Plot No. C-27 'G' Block, Bandra Kurla Complex Bandra (East), Mumbai 400 051 Maharashtra, India	**IIFL Capital Services Limited (*formerly known as IIFL Securities Limited*)** 24th Floor, One Lodha Place Senapati Bapat Marg, Lower Parel (West) Mumbai 400 013 Maharashtra, India
Jefferies India Private Limited Level 16, Express Towers, Nariman Point, Mumbai – 400 021, Maharashtra, India	**Motilal Oswal Investment Advisors Limited** Motilal Oswal Tower Rahimtullah Sayani Road Opposite Parel ST Depot Prabhadevi, Mumbai 400 025 Maharashtra, India

Domestic Legal Counsel to the Book Running Lead Managers
Cyril Amarchand Mangaldas
3rd Floor, Prestige Falcon Towers
19, Brunton Road, Off M.G. Road
Bengaluru - 560 025, Karnataka, India

International Legal Counsel
Hogan Lovells Lee & Lee
50 Collyer Quay, #10-01 OUE
Bayfront, Singapore 049321

Domestic Legal Counsel to the Company
Khaitan & Co
Max Towers
7th & 8th Floors, Sector 16B
Noida, Gautam Buddh Nagar 201 301
Uttar Pradesh, India